Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (71-80 of 206) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|September 2, 2011
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week resultsBrian Gazzard, Claudine Duvivier, Christian Zagler, et al.
Leukemia & Lymphoma|June 30, 2004
Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levelsTom Newsom-Davis, Mark Bower, Adrian Wildfire, et al.
AIDS (London, England)|June 5, 2007
Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patientsGuglielmo Rosignoli, Alison Cranage, Catherine Burton, et al.
Blood|February 20, 2009
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman diseaseMark Bower, Ophelia Veraitch, Richard Szydlo, et al.
Blood|November 21, 2007
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman diseaseTom Powles, Justin Stebbing, Silvia Montoto, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2005
The effect of statins on HIV rebound and blipsLaura Waters, Justin Stebbing, Rachael Jones, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 23, 2008
A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapyTeresa L Kauf, Neil Roskell, Arran Shearer, et al.
AIDS (London, England)|July 11, 2003
A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcomaSimon Portsmouth, Justin Stebbing, Jas Gill, et al.
Antiviral Therapy|March 8, 2006
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapyGraeme Moyle, Christopher Higgs, Alastair Teague, et al.
The Journal of Antimicrobial Chemotherapy|May 25, 2005
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterolVictoria Latham, Justin Stebbing, Sundhiya Mandalia, et al.
Pageof 21

Showing results (71-80 of 206) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|September 2, 2011
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week resultsBrian Gazzard, Claudine Duvivier, Christian Zagler, et al.
Leukemia & Lymphoma|June 30, 2004
Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levelsTom Newsom-Davis, Mark Bower, Adrian Wildfire, et al.
AIDS (London, England)|June 5, 2007
Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patientsGuglielmo Rosignoli, Alison Cranage, Catherine Burton, et al.
Blood|February 20, 2009
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman diseaseMark Bower, Ophelia Veraitch, Richard Szydlo, et al.
Blood|November 21, 2007
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman diseaseTom Powles, Justin Stebbing, Silvia Montoto, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2005
The effect of statins on HIV rebound and blipsLaura Waters, Justin Stebbing, Rachael Jones, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 23, 2008
A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapyTeresa L Kauf, Neil Roskell, Arran Shearer, et al.
AIDS (London, England)|July 11, 2003
A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcomaSimon Portsmouth, Justin Stebbing, Jas Gill, et al.
Antiviral Therapy|March 8, 2006
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapyGraeme Moyle, Christopher Higgs, Alastair Teague, et al.
The Journal of Antimicrobial Chemotherapy|May 25, 2005
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterolVictoria Latham, Justin Stebbing, Sundhiya Mandalia, et al.
Pageof 21